Are N-methyl-D-aspartate receptor antagonists or acetylcholinesterase inhibitors more effective in slowing cognitive decline in Parkinson's disease dementia?

    loading  Checking for direct PDF access through Ovid

Abstract

EVIDENCE-BASED ANSWER

Currently, no head-to-head trials have compared the efficacy of acetylcholinesterase inhibitors with N-methyl-D-aspartate receptor antagonists for Parkinson's disease dementia. Acetylcholinesterase inhibitors minimally slow cognitive decline and improve language and memory function, although these changes may not be clinically significant (SOR: B, meta-analysis of RCTs and an RCT). N-methyl-D-aspartate receptor antagonists do not slow cognitive decline (SOR: B, RCT).

Related Topics

    loading  Loading Related Articles